What’s Driving Australia’s HealthTech Investment Boom?
Australia’s HealthTech market is accelerating as AI, government funding, venture capital, and mega-deals drive rapid growth across digital healthcare and MedTech. (Stock Photo)
Australia’s HealthTech sector is entering a new phase as artificial intelligence, private investment, and government spending accelerate the digital transformation of healthcare.
The national digital health market, valued at US$8.9 billion in 2025, is projected to reach US$31.1 billion by 2034, representing a compound annual growth rate of 14.92%. Growth is being driven by the integration of AI into clinical workflows, rising demand for remote care, and expanding investment in healthcare infrastructure.
Government Funding Meets Private Capital
Australia’s digital health ecosystem is moving beyond the post-COVID normalization period toward broader technology integration. Digital therapeutics, remote patient monitoring, and cloud-based clinical software are among the fastest-growing areas.
The wider Healthcare IT market is valued at US$11.4 billion and is forecast to reach US$31.6 billion by 2034. Telehealth, now a more established service at about US$542 million, is projected to reach US$2.56 billion over the same period, while the MedTech market could grow from US$8.9 billion to US$14 billion.
Public funding is providing a major catalyst. The 2026 Federal Budget included AUD$598.3 million to modernize My Health Record and introduce sharing-by-default, AUD$745.1 million for Medicare digital integration, and AUD$358.5 million for an upgraded NDIS payment platform. The government’s National Reconstruction Fund Corporation has also begun making equity investments in medical science.
Private capital is returning at the same time. HealthTech venture fundraising exceeded AUD$620 million in the first two months of 2026, with specialized funds and superannuation investors such as Aware Super playing a growing role.
Mega-Deals Signal Investor Confidence
M&A activity is reinforcing the sector’s momentum. One of the largest transactions was US telehealth company Hims & Hers’ acquisition of Australian digital health company Eucalyptus for up to US$1.15 billion, or about AUD$1.6 billion.
Other notable transactions include Quadrant Private Equity’s acquisition of diagnostic imaging network Carlisle Health at an enterprise value of approximately AUD$200 million, and TA Associates’ acquisition of Clanwilliam Group for about US$450 million.
Strategic consolidators including Telstra Health and Magentus are also continuing to acquire specialized practice management, radiology and laboratory software platforms.
Investment is particularly concentrated in technologies addressing healthcare workforce pressures and chronic disease. Clinical AI platforms are attracting capital for automated disease detection, while remote monitoring and clinical-grade wearables are benefiting from hospital-at-home models.
Ambient AI is another fast-growing category, with tools that automatically generate clinical notes and electronic health-record documentation helping reduce administrative workloads. Digitalization of aged care and disability services is also gaining attention as providers respond to regulatory and NDIS reforms.
Australia Builds a Global HealthTech Pipeline
Australia is producing companies across diagnostic AI, neurotechnology and preventive health.
Harrison.ai, through its Annalise.ai platform, develops AI tools for analyzing chest X-rays and head CT scans and has secured AUD$179 million in Series C funding, backed by Aware Super and the National Reconstruction Fund Corporation.
Heidi Health, an ambient AI documentation platform, processes more than 1.5 million sessions globally each week, while Synchron is developing brain-computer interface technology designed to enable people with paralysis to control digital devices.
Other companies are also targeting specialized markets. Pro Medicus has established a global position in enterprise radiology imaging software, while Everlab combines full-body MRI scanning with AI-based health intelligence for early disease detection.
Despite the momentum, challenges remain. Australia lacks a permanent national reimbursement pathway for software-based digital therapeutics and remote patient monitoring, leaving some technologies dependent on pilot programs.
Cybersecurity and data privacy are also major concerns, while a shortage of domestic late-stage capital could constrain companies seeking AUD$100 million or more in growth funding.
For Australia’s HealthTech industry, the next phase will depend on converting strong technology capabilities and growing investment into scalable healthcare solutions that can compete in both domestic and international markets.
Source: Nelson Advisors
🚀 Connect with Global Leaders in Aging & Care Innovation!
Sourcingcares links international partners in aging care, long-term care, and health technology, fostering collaboration and driving solutions for a changing world. Our initiatives include Cares Expo Taipei, where the future of elder care takes shape!
🔗 Follow us for insights & opportunities:
📌 Facebook: sourcingcares
📌 LinkedIn: sourcingcares
📍 Explore more at Cares Expo Taipei!
